- About us
- About Vaccines
- Media centre
- Become a member
- VE Day 2013
Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.
How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access
Vaccines Europe acts as the cohesive voice of the Europe-based vaccine industry sector and is a trusted partner for public authorities. Find out more about our association and contribution to Europe.
With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.
Vaccines Europe (VE), The European Vaccine Initiative (EVI), The Sclavo Vaccines Association (SVA) and EATRIS due to meet in Brussels for penultimate workshop ahead of the final project summit with top stakeholders in the vaccine field.
Key opinion leaders in the field of vaccine research and development are meeting in the upcoming IPROVE consultation workshop in Brussels on 12 and 13 March 2015. The objective of the workshop is to formulate a consensus on future vaccine R&I activities and identify key gaps and needs to be addressed over the coming years to bolster vaccine innovation and connect across Europe the appropriate expertise needed to meet the challenge of current medical needs. Read more…
The European Centre for Disease Prevention and Control (ECDC) has just published a new Technical Report assessing vaccination coverage rates for the influenza season 2012-13 compared against the previous season 2011-2012.
The report shows that although it is common for EU Member States to have recommendations in place for targeted or at-risk groups, such as older people, pregnant women, those suffering from chronic conditions and healthcare workers, vaccination coverage rates remain stagnant or in some cases show to be declining compared to previous seasons. Read more…
Vaccines Europe welcomes the Council Conclusions on “Vaccinations as an effective tool in public health”, adopted today by the EU Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council. The adopted Conclusions are a fundamental development on the EU political agenda for public health, and constitute an important basis to strengthen EU action in supporting Member States to implement effective immunisation programmes in the years to come.
The Council Conclusions recognise the core challenges affecting the “state of health” of vaccination programmes in the EU, which go from costly outbreaks of preventable diseases to the need of addressing demographic ageing through a life-course approach to vaccination. Read more…